Bartalucci, Niccolò <br/><br/>
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.  [electronic resource] 

 -  Clinical lymphoma, myeloma & leukemia  Sep 2013 
 - S307-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>2152-2669 
<br/><br/><label>Standard No.: </label>10.1016/j.clml.2013.07.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Humans<br/>Janus Kinase 2--antagonists & inhibitors<br/>Molecular Targeted Therapy<br/>Myeloproliferative Disorders--drug therapy<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Signal Transduction--drug effects<br/>TOR Serine-Threonine Kinases--metabolism